TickerFacts.

Company research / QURE

uniQure N.V. (QURE)

Build a valuation ↗↓ Download CSV

CIK 0001590560 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, uniQure N.V. reported revenue of $16.10M. Revenue fell 40.6% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $18.09M.

Key ratios (year ended 2025-12-31)

89.5%
Gross margin (computed)
n/m
Operating margin
n/m
Net margin
-100.0%
Return on year-end equity
-40.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-29

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-03-31		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$18.09M$16.10M$27.12M$15.84M$106.48M$524.00M$37.51M$7.28M$11.28M$13.11M$25.10M
Cost of Revenue$1.71M$1.69M$1.27M$65.0K$1.25M$24.98M$2.90M$1.65M$1.20M$817.0K$1.35M
Gross Profit (computed)$16.39M$14.41Mn/an/an/an/a$34.62M$5.63M$10.08M$12.29M$23.75M
R&D Expense$133.71M$140.67M$143.78M$214.86M$197.59M$143.55M$122.40M$94.74M$74.81M$72.17M$72.51M
Operating Income-$191.74M-$185.35M-$184.29M-$282.87M-$143.16M$310.62M-$125.43M-$121.14M-$88.23M-$71.34M-$71.95M
Depreciation & Amortization$13.19M$14.76M$12.64M$11.90M$8.54M$7.30M$10.65M$6.67M$12.41M$7.54Mn/a
EBITDA-$178.55M-$170.59M-$171.65M-$270.97M-$134.62M$317.92M-$114.78M-$114.47M-$75.82M-$63.80Mn/a
Net Income-$208.87M-$198.97M-$239.56M-$308.48M-$126.79M$329.59M-$125.02M-$124.20M-$83.30M-$79.26M-$73.37M
EPS (Diluted)n/a-$3.46-$4.92-$6.47-$2.71$7.04-$2.81-$3.11n/an/an/a
Total Assets$778.71M$824.91M$556.54M$831.69M$704.96M$809.18M$340.39M$448.63M$273.91M$209.64M$190.26M
Total Liabilities$629.36M$626.01M$563.29M$624.02M$228.96M$213.40M$96.49M$125.57M$94.30M$120.28M$126.63M
Long-Term Debtn/a$71.92M$66.02M$147.57M$144.49M$135.59M$42.41M$46.53M$48.18M$23.96Mn/a
Shareholders' Equity$149.34M$198.90M-$6.75M$207.67M$476.01M$595.78M$243.91M$323.06M$179.61M$89.36M$63.63M
Cash & Equivalents$139.99M$80.24M$158.93M$241.36M$228.01M$556.26M$244.93M$377.79M$234.90M$159.37M$132.50M
Operating Cash Flow-$172.11M-$177.96M-$182.73M-$145.93M-$145.06M$287.96M-$134.83M-$98.68M-$76.04M-$64.27M-$72.19M
Capital Expenditures$453.0K$439.0K$3.37M$7.15M$17.69M$17.44M$7.27M$5.65M$2.38M$4.46M$15.29M
Free Cash Flow-$172.56M-$178.40M-$186.10M-$153.08M-$162.75M$270.52M-$142.10M-$104.33M-$78.42M-$68.73M-$87.48M
Shares Outstanding63.03M62.34M48.99M47.83M46.97M46.30M44.78M43.71M37.35M31.34M25.26M
Weighted Average Diluted Sharesn/a57.50M48.65M47.67M46.74M46.84M44.47M40.00Mn/an/an/a
EPS (Basic)n/a-$3.46-$4.92-$6.47-$2.71$7.17-$2.81-$3.11n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView